Adma Biologics is a biotechnology company that specializes in the development and manufacturing of immune globulin therapies and other biologics for patients suffering from immune deficiencies and specific infectious diseases. The company focuses on harnessing human plasma to create products that can improve immune response and provide critical support for individuals with compromised immune systems. Through its innovative research and commitment to quality, Adma aims to deliver safe and effective therapies that enhance patient outcomes and overall health. Read More
RAMSEY, N.J. and BOCA RATON, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that Adam Grossman, President and Chief Executive Officer, will participate in a podium presentation at the J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 9:45 a.m. PT.
ANI is firing on all cylinders operationally, which makes this exit less about fundamentals and more about portfolio discipline at a moment when expectations might be sky-high.
ADMA Biologics exemplifies GARP investing with strong revenue & earnings growth, high profitability, and a reasonable valuation relative to its biotech peers.
ADMA Biologics (NASDAQ:ADMA) meets Minervini’s Trend Template with strong technicals and high-growth fundamentals, making it a candidate for momentum investors.
